The medications now target multiple organ systems, including the pancreas, stomach, brain, heart, kidneys, immune system, skeletal muscle, adipose tissue, and liver, addressing multiple chronic conditions simultaneously rather than just treating obesity
Adjustments to dose, titration speed, nutrition strategy, or timing are common and often restore forward progress
The results showed that tirzepatide led to greater reductions in HbA1c levels, fasting serum glucose, and body weight compared to placebo or a selective GLP-1 receptor agonist
Two main classes exist: GHRH analogs (CJC-1295, Tesamorelin): These mimic growth hormone-releasing hormone, activate GHRH receptors on pituitary, and stimulate GH synthesis and release